Does the media favor TXG or PACB?

In the previous week, 10x Genomics had 9 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for 10x Genomics and 3 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.67 beat Pacific Biosciences of California's score of 0.15 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pacific Biosciences of California 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, VLTO or TXG?

Veralto has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Veralto, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veralto $5.50B 4.27 $940M $3.96 24.35 10x Genomics $642.82M 9.45 -$43.54M -$0.17 N/A

Is VLTO or TXG more profitable?

Veralto has a net margin of 17.35% compared to 10x Genomics' net margin of -3.55%. Veralto's return on equity of 34.76% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Veralto 17.35% 34.76% 13.38% 10x Genomics -3.55% -2.86% -2.23%

Does the media refer more to VLTO or TXG?

In the previous week, Veralto had 31 more articles in the media than 10x Genomics. MarketBeat recorded 43 mentions for Veralto and 12 mentions for 10x Genomics. Veralto's average media sentiment score of 0.89 beat 10x Genomics' score of 0.67 indicating that Veralto is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veralto 24 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TXG or FTV?

Fortive has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Fortive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.45 -$43.54M -$0.17 N/A Fortive $4.16B 4.40 $579.20M $1.69 35.89

Is TXG or FTV more profitable?

Fortive has a net margin of 12.38% compared to 10x Genomics' net margin of -3.55%. Fortive's return on equity of 15.33% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Fortive 12.38% 15.33% 8.23%

Does the media favor TXG or FTV?

In the previous week, Fortive had 11 more articles in the media than 10x Genomics. MarketBeat recorded 23 mentions for Fortive and 12 mentions for 10x Genomics. Fortive's average media sentiment score of 0.84 beat 10x Genomics' score of 0.67 indicating that Fortive is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Fortive 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TXG or NVMI?

Nova has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.45 -$43.54M -$0.17 N/A Nova $880.58M 14.92 $259.22M $8.02 51.56

Is TXG or NVMI more profitable?

Nova has a net margin of 29.21% compared to 10x Genomics' net margin of -3.55%. Nova's return on equity of 21.77% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Nova 29.21% 21.77% 12.56%

Does the media prefer TXG or NVMI?

In the previous week, 10x Genomics had 1 more articles in the media than Nova. MarketBeat recorded 12 mentions for 10x Genomics and 11 mentions for Nova. Nova's average media sentiment score of 1.35 beat 10x Genomics' score of 0.67 indicating that Nova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Nova 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TXG or RVTY?

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.45 -$43.54M -$0.17 N/A Revvity $2.86B 4.34 $241.20M $2.09 53.14

Is TXG or RVTY more profitable?

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Revvity 8.26% 8.00% 4.83%

Does the media favor TXG or RVTY?

In the previous week, Revvity had 3 more articles in the media than 10x Genomics. MarketBeat recorded 15 mentions for Revvity and 12 mentions for 10x Genomics. Revvity's average media sentiment score of 0.80 beat 10x Genomics' score of 0.67 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Revvity 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

10x Genomics (TXG) Competitors

$47.86 +0.85 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$47.94 +0.08 (+0.17%)

As of 04:50 PM Eastern

Compare

TXG vs. PACB, VLTO, FTV, NVMI, and RVTY

Should you buy 10x Genomics stock or one of its competitors? MarketBeat compares 10x Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 10x Genomics include Pacific Biosciences of California (PACB), Veralto (VLTO), Fortive (FTV), Nova (NVMI), and Revvity (RVTY).

How does 10x Genomics compare to Pacific Biosciences of California?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

In the previous week, 10x Genomics had 9 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for 10x Genomics and 3 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.67 beat Pacific Biosciences of California's score of 0.15 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.45	-$43.54M	-$0.17	N/A
Pacific Biosciences of California	$160.01M	2.80	-$546.38M	-$0.43	N/A

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

10x Genomics presently has a consensus price target of $32.08, suggesting a potential downside of 32.96%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 27.31%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Veralto?

Veralto (NYSE:VLTO) and 10x Genomics (NASDAQ:TXG) are related companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Veralto has a net margin of 17.35% compared to 10x Genomics' net margin of -3.55%. Veralto's return on equity of 34.76% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veralto	17.35%	34.76%	13.38%
10x Genomics	-3.55%	-2.86%	-2.23%

Veralto currently has a consensus price target of $110.90, suggesting a potential upside of 15.00%. 10x Genomics has a consensus price target of $32.08, suggesting a potential downside of 32.96%. Given Veralto's stronger consensus rating and higher possible upside, research analysts plainly believe Veralto is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veralto	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Veralto has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Veralto, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veralto	$5.50B	4.27	$940M	$3.96	24.35
10x Genomics	$642.82M	9.45	-$43.54M	-$0.17	N/A

91.3% of Veralto shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 0.4% of Veralto shares are held by insiders. Comparatively, 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Veralto has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

In the previous week, Veralto had 31 more articles in the media than 10x Genomics. MarketBeat recorded 43 mentions for Veralto and 12 mentions for 10x Genomics. Veralto's average media sentiment score of 0.89 beat 10x Genomics' score of 0.67 indicating that Veralto is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veralto	24 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Veralto beats 10x Genomics on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Fortive?

10x Genomics (NASDAQ:TXG) and Fortive (NYSE:FTV) are related companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Fortive had 11 more articles in the media than 10x Genomics. MarketBeat recorded 23 mentions for Fortive and 12 mentions for 10x Genomics. Fortive's average media sentiment score of 0.84 beat 10x Genomics' score of 0.67 indicating that Fortive is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Fortive	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics currently has a consensus price target of $32.08, indicating a potential downside of 32.96%. Fortive has a consensus price target of $63.10, indicating a potential upside of 4.04%. Given Fortive's higher possible upside, analysts clearly believe Fortive is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fortive	2 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fortive has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Fortive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.45	-$43.54M	-$0.17	N/A
Fortive	$4.16B	4.40	$579.20M	$1.69	35.89

10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Fortive has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 94.9% of Fortive shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 0.7% of Fortive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Fortive has a net margin of 12.38% compared to 10x Genomics' net margin of -3.55%. Fortive's return on equity of 15.33% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Fortive	12.38%	15.33%	8.23%

Summary

Fortive beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Nova?

10x Genomics (NASDAQ:TXG) and Nova (NASDAQ:NVMI) are related companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

10x Genomics currently has a consensus price target of $32.08, suggesting a potential downside of 32.96%. Nova has a consensus price target of $556.67, suggesting a potential upside of 34.62%. Given Nova's stronger consensus rating and higher possible upside, analysts clearly believe Nova is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Nova	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Nova has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.45	-$43.54M	-$0.17	N/A
Nova	$880.58M	14.92	$259.22M	$8.02	51.56

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 83.0% of Nova shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 1.0% of Nova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nova has a net margin of 29.21% compared to 10x Genomics' net margin of -3.55%. Nova's return on equity of 21.77% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Nova	29.21%	21.77%	12.56%

10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Nova has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

In the previous week, 10x Genomics had 1 more articles in the media than Nova. MarketBeat recorded 12 mentions for 10x Genomics and 11 mentions for Nova. Nova's average media sentiment score of 1.35 beat 10x Genomics' score of 0.67 indicating that Nova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Nova	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nova beats 10x Genomics on 12 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Revvity?

10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Revvity	8.26%	8.00%	4.83%

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Revvity had 3 more articles in the media than 10x Genomics. MarketBeat recorded 15 mentions for Revvity and 12 mentions for 10x Genomics. Revvity's average media sentiment score of 0.80 beat 10x Genomics' score of 0.67 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Revvity	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics presently has a consensus target price of $32.08, indicating a potential downside of 32.96%. Revvity has a consensus target price of $108.36, indicating a potential downside of 2.43%. Given Revvity's higher possible upside, analysts clearly believe Revvity is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Revvity	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.45	-$43.54M	-$0.17	N/A
Revvity	$2.86B	4.34	$241.20M	$2.09	53.14

Summary

Revvity beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.08B	$9.07B	$6.80B	$13.02B
Dividend Yield	N/A	1.47%	2.60%	10.03%
P/E Ratio	-281.53	59.25	279.73	25.56
Price / Sales	9.45	105.80	649.61	116.36
Price / Cash	N/A	25.63	28.64	34.82
Price / Book	7.67	5.15	11.12	6.36
Net Income	-$43.54M	$57.47B	$3.48B	$347.58M
7 Day Performance	1.72%	1.28%	2.67%	3.24%
1 Month Performance	22.69%	-2.23%	-2.70%	-2.00%
1 Year Performance	249.85%	15.81%	64.43%	21.31%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	1.7132 of 5 stars	$47.86 +1.8%	$32.08 -33.0%	+259.4%	$6.08B	$642.82M	N/A	1,240	Upcoming Earnings
PACB Pacific Biosciences of California	2.1459 of 5 stars	$1.36 flat	$1.83 +34.8%	+6.8%	$422.42M	$160.01M	N/A	730
VLTO Veralto	4.7228 of 5 stars	$94.14 +2.3%	$106.33 +13.0%	-9.3%	$22.60B	$5.50B	24.33	17,000	Earnings Report
FTV Fortive	3.7002 of 5 stars	$62.85 +0.9%	$63.00 +0.2%	+27.9%	$18.84B	$4.16B	37.63	10,000	Earnings Report
NVMI Nova	4.8631 of 5 stars	$428.88 -2.1%	$556.67 +29.8%	+49.4%	$13.92B	$880.58M	53.48	1,612	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, VLTO, FTV, NVMI, and RVTY

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Veralto?

Summary

How does 10x Genomics compare to Fortive?

Summary

How does 10x Genomics compare to Nova?

Summary

How does 10x Genomics compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, VLTO, FTV, NVMI, and RVTY

How does 10x Genomics compare to Pacific Biosciences of California?

Which has more volatility & risk, TXG or PACB?

Does the media favor TXG or PACB?

Do institutionals and insiders have more ownership in TXG or PACB?

Which has stronger valuation and earnings, TXG or PACB?

Is TXG or PACB more profitable?

Do analysts rate TXG or PACB?

Summary

How does 10x Genomics compare to Veralto?

Is VLTO or TXG more profitable?

Do analysts recommend VLTO or TXG?

Which has preferable earnings & valuation, VLTO or TXG?

Do institutionals & insiders hold more shares of VLTO or TXG?

Which has more volatility & risk, VLTO or TXG?

Does the media refer more to VLTO or TXG?

Summary

How does 10x Genomics compare to Fortive?

Does the media favor TXG or FTV?

Do analysts prefer TXG or FTV?

Which has preferable earnings & valuation, TXG or FTV?

Which has more volatility and risk, TXG or FTV?

Do institutionals and insiders have more ownership in TXG or FTV?

Is TXG or FTV more profitable?

Summary

How does 10x Genomics compare to Nova?

Do analysts rate TXG or NVMI?

Which has stronger earnings and valuation, TXG or NVMI?

Do insiders & institutionals hold more shares of TXG or NVMI?

Is TXG or NVMI more profitable?

Which has more volatility and risk, TXG or NVMI?

Does the media prefer TXG or NVMI?

Summary

How does 10x Genomics compare to Revvity?

Which has more volatility & risk, TXG or RVTY?

Is TXG or RVTY more profitable?

Do insiders and institutionals have more ownership in TXG or RVTY?

Does the media favor TXG or RVTY?

Do analysts recommend TXG or RVTY?

Which has better earnings and valuation, TXG or RVTY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools